Please login to the form below
Ablynx
This page shows the latest Ablynx news and features for those working in and with pharma, biotech and healthcare.
Second TULIP trial resurrects AZ’s lupus drug anifrolumab
dapirolizumab pegol, Ablynx’ IL-6 inhibitor vobarilizumab, and ImmuPharma’s immune modulator rigerimod.
Latest news
-
Hudson named Brandicourt’s successor as Sanofi’s CEO
He also bolstered the company’s pipeline with acquisitions of Ablynx and Bioverativ for 3.9bn and $11.6bn, respectively, building a franchise in rare blood diseases, but missed out to ... atopic dermatitis and asthma therapy Dupixent (dupilumab) and
-
Sanofi exits R&D pact with Alnylam on rare disease
Bioverativ an Ablynx last year. ... Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).
-
Sanofi gets US okay for $270,000 blood disorder drug Cablivi
Prior to its takeover, Ablynx had suggested peak sales of more than 1bn were possible. ... It is the first drug to be approved for marketing based on Ablynx’s ‘nanobody’ technology, a new class of therapeutic proteins based on single-domain
-
Neoantigen player Achilles gets OK for first clinical trial
at Ablynx before it was sold to Sanofi last year for $4.8bn – took over as chair of the UK biotech. ... The company has made no secret of its intention to follow an Ablynx-like path and become an integrated biotech focused on developing and
-
Duchenne UK backs Evox dystrophin delivery project
de Fougerolles, who joined the company last year from Ablynx.
More from news
Approximately 8 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
acquisition of Belgium’s Ablynx by Sanofi.
-
30 Women Leaders in UK Healthcare (part 2)
corporate roles for Vertex and Ablynx.
-
Deal Watch January 2018
bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.
-
Deal Watch November 2015
410. Ablynx. Novo Nordisk. Discovery collaboration, licence. Multi specific Nanobody drug candidates in undisclosed TA with option to expand to second Nanobody programme.
-
Deal Watch table for February 2014
25, 000. Ablynx / Merck &Co. Collaboration. Nanobody candidates to target “immune checkpoint modulators”.
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
PureTech Health appoints new chief financial officer
Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma
-
Apitope strengthens its board with new director
He has also served on several boards including Ablynx, Evotec and Acambis.
-
Ablynx reshuffles its board again
Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman. ... Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable
-
Robert Freisen joins Ablynx
Ablynx, recently acquired by Sanofi, has appointed Robert Freisen to the role of chief scientific officer, who will head the biopharma’s scientific research and technology activities. ... He said: “I have long admired Ablynx and am excited to join
-
Novo Nordisk target Ablynx reshuffles its board
Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk. ... Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured)
More from appointments
Approximately 5 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- Gut instincts lead Takeda to GI pipeline success
- New study identifies drugs that are safe to use in COVID-19 treatment
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
